Annals of Allergy Asthma & Immunology最新文献

{"title":"Clinical, immunologic, and treatment burden of nonsteroidal anti-inflammatory drug–exacerbated cutaneous disease","authors":"Dong-Hyeon Suh MS ,&nbsp;Jieun Seo MS ,&nbsp;Chang-June Choi MS, PhD ,&nbsp;Young-Min Ye MD, PhD ,&nbsp;Yooseob Shin MD, PhD ,&nbsp;Hae-Sim Park MD, PhD","doi":"10.1016/j.anai.2025.11.028","DOIUrl":"10.1016/j.anai.2025.11.028","url":null,"abstract":"<div><h3>Background</h3><div>Nonsteroidal anti-inflammatory drugs (NSAIDs) are major exacerbating factors in approximately one-third of patients with chronic spontaneous urticaria (CSU), contributing to disease chronicity and severity. However, comprehensive comparisons of clinical characteristics and treatment responses remain limited.</div></div><div><h3>Objective</h3><div>To analyze baseline characteristics, immunologic parameters, and treatment outcomes in patients with NSAID-exacerbated chronic disease (NECD) compared with those with NSAID-tolerant chronic urticaria (NTCU), using long-term outcome models in a large, real-world clinical cohort.</div></div><div><h3>Methods</h3><div>From a cohort of 9632 adult patients with CSU, 966 patients with NECD were identified by diagnostic codes and were analyzed against the remaining patients with NTCU. Clinical and laboratory findings, medication requirements, and long-term clinical outcomes were compared between the 2 groups.</div></div><div><h3>Results</h3><div>The disease duration was significantly longer in patients with NECD (42.7 ± 46.3 vs 21.9 ± 30.9 months, <em>P</em> &lt; .001), and the prevalence of angioedema was higher (58.1% vs 23.4%, <em>P</em> &lt; .001). They required longer treatment durations with antihistamines and leukotriene receptor antagonists (<em>P</em> &lt; .001 for all). The daily dose of systemic corticosteroids was also higher (11.7 ± 6.1 vs 10.4 ± 6.9 mg, <em>P</em> &lt; .001). Patients with NECD also had longer omalizumab treatment durations, with no difference in cyclosporine use.</div></div><div><h3>Conclusion</h3><div>Our findings confirm that NECD represents a more chronic and treatment-resistant phenotype within patients with CSU. These results provide valuable insights into the distinct clinical and immunologic profiles of NECD, underscoring its higher disease burden and refractory nature.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 295-300"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Characterization and cluster analyses of elderly asthma in comparison with non-elderly asthma patients in Japan’ [Annals of Allergy, Asthma & Immunology, Volume 130, Issue 5 (2023) 607-616.e3]","authors":"Maho Suzukawa MD, PhD ,&nbsp;Ken Ohta MD, PhD ,&nbsp;Hiroya Hashimoto PhD ,&nbsp;Yoshitaka Oyamada MD, PhD ,&nbsp;Mari Miki MD, PhD ,&nbsp;Mitsumasa Ogawara MD, PhD ,&nbsp;Yoshikazu Inoue MD, PhD ,&nbsp;Akiko M. Saito MD, PhD ,&nbsp;Yuma Fukutomi MD, PhD ,&nbsp;Nobuyuki Kobayashi MD ,&nbsp;Masami Taniguchi MD, PhD ,&nbsp;NHOM-Asthma study group","doi":"10.1016/j.anai.2025.12.009","DOIUrl":"10.1016/j.anai.2025.12.009","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 368-369"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145967733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two little brats","authors":"Erin L. Reigh MD, MS","doi":"10.1016/j.anai.2025.10.015","DOIUrl":"10.1016/j.anai.2025.10.015","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 270-271"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching to race-neutral spirometry equations reveals restrictive, not obstructive, patterns","authors":"John M. Kelso MD","doi":"10.1016/j.anai.2025.10.030","DOIUrl":"10.1016/j.anai.2025.10.030","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 363-364"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From broad application to targeted use: The changing landscape of aspirin therapy after desensitization (ATAD) in aspirin-exacerbated respiratory disease (AERD)","authors":"Blanka Kaplan MD ,&nbsp;Andrew White MD","doi":"10.1016/j.anai.2025.10.025","DOIUrl":"10.1016/j.anai.2025.10.025","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 246-247"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open access is essential for research funded by the National Institutes of Health (NIH)","authors":"Mitchell H. Grayson MD","doi":"10.1016/j.anai.2026.01.007","DOIUrl":"10.1016/j.anai.2026.01.007","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Page 248"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing aspirin therapy after desensitization (ATAD) tolerance in aspirin-exacerbated respiratory disease (AERD) patients","authors":"Lancelot P. Herpin BA ,&nbsp;Alexa M. Finuoli BA ,&nbsp;Alan D. Workman MD, MTR ,&nbsp;Si Hao Tang BA ,&nbsp;Krithika Kuppusamy BS ,&nbsp;Michael A. Kohanski MD, PhD ,&nbsp;James N. Palmer MD ,&nbsp;Nithin D. Adappa MD ,&nbsp;Jennifer E. Douglas MD ,&nbsp;John V. Bosso MD","doi":"10.1016/j.anai.2025.09.021","DOIUrl":"10.1016/j.anai.2025.09.021","url":null,"abstract":"<div><h3>Background</h3><div>For more than 40 years, aspirin desensitization with aspirin therapy after desensitization (ATAD) has been a recognized treatment for aspirin-exacerbated respiratory disease (AERD). This study aimed to characterize the rate of ATAD-associated complications leading to discontinuation and identify associated risk factors.</div></div><div><h3>Objective</h3><div>To evaluate the rate and causes of ATAD intolerance and identify demographic factors that may predict intolerance in patients with AERD.</div></div><div><h3>Methods</h3><div>A total of 360 patients with AERD who underwent aspirin desensitization and ATAD at a tertiary center from August 2016 to April 2024 were reviewed. A joint model combining linear mixed and Cox proportional hazards models was used to assess associations between demographic factors, aspirin dosage, and ATAD intolerance.</div></div><div><h3>Results</h3><div>Of 278 patients included, 4 (1.4%) failed desensitization and 44 (15.8%) discontinued ATAD. Furthermore, 10 patients (3.6%) experienced major complications requiring emergency department visit or hospitalization. Common discontinuation causes included gastrointestinal symptoms, anaphylaxis, cutaneous reactions, and airway symptom exacerbation. On average, aspirin dosage decreased overtime (−10 mg daily per month; <em>P</em> &lt; .0001) and was lower in older patients (−7.78 mg daily; <em>P</em> &lt; .0001), reflecting current dosage practices. Peri-/post-menopausal female status was associated with reduced ATAD intolerance risk (hazard ratio [HR] = 0.4; <em>P</em> = .041), whereas pre-menopausal status with a nonsignificant increase (HR = 2.28; <em>P</em> = .087). ATAD intolerance was more likely in Hispanic/Latino (HR = 8.2; <em>P</em> = .0013) and African American patients (HR = 4.03; <em>P</em> = .0015) and increased modestly with age (HR = 1.08; <em>P</em> &lt; .0001). Longitudinal aspirin dosage was not associated with overall intolerance or intolerance due to gastrointestinal complications specifically after adjustment.</div></div><div><h3>Conclusion</h3><div>ATAD tolerance was lower in Hispanic/Latino, African American, and older patients, higher in peri-/post-menopausal females, and not associated with longitudinal aspirin dosage.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 288-294"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and genetic study in factor XII hereditary angioedema in a population from Southern Spain","authors":"Teresa de Aramburu Mera MD, PhD ,&nbsp;Krasimira Baynova MD ,&nbsp;José Manuel Lucena Soto MD, PhD ,&nbsp;José Raúl García Lozano MD, PhD ,&nbsp;Stefan Cimbollek MD","doi":"10.1016/j.anai.2025.11.003","DOIUrl":"10.1016/j.anai.2025.11.003","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 358-359"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema","authors":"Courtney Olson MD ,&nbsp;Michael Lionetti BA ,&nbsp;Christine Poulos PhD ,&nbsp;Tamara Ray MBA ,&nbsp;Lorena Lopez-Gonzalez PhD ,&nbsp;Sandra Nestler-Parr PhD ,&nbsp;Patrick Gillard PharmD ,&nbsp;Daniel Soteres MD","doi":"10.1016/j.anai.2025.12.011","DOIUrl":"10.1016/j.anai.2025.12.011","url":null,"abstract":"<div><h3>Background</h3><div>Long-term prophylaxis (LTP) can help manage hereditary angioedema (HAE). With increasing LTP treatment options, understanding patients’ preferences is important for shared decision-making.</div></div><div><h3>Objective</h3><div>To understand the way individuals with HAE assess the importance of LTP treatment attributes, their LTP treatment preferences, and the impact of disease and treatment attributes on their willingness to switch LTP.</div></div><div><h3>Methods</h3><div>We conducted an online survey in 2023 among US adults (aged ≥18 years) self-reporting an HAE diagnosis and receiving treatment (LTP, on-demand, or both) or experiencing at least 1 attack in the past 3 months. Best-worst scaling and a discrete choice experiment assessed LTP preferences. A behavior change model assessed willingness to switch LTP.</div></div><div><h3>Results</h3><div>A total of 150 individuals completed the survey. Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes. Route of administration and convenience were more than twice as important as dosing frequency. Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%). Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.</div></div><div><h3>Conclusion</h3><div>Effectiveness was the primary driver of LTP preference; other factors were also important, including convenience. When effectiveness was equivalent, oral administration was preferred to injectable administration. Individuals with HAE were moderately willing to switch their LTP. By better understanding patients’ treatment preferences, health care professionals can individualize LTP recommendations.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Pages 322-332"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145812163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crystal ball: Predictions for urticaria treatment and lung function trajectories","authors":"Mitchell H. Grayson MD","doi":"10.1016/j.anai.2026.01.005","DOIUrl":"10.1016/j.anai.2026.01.005","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 3","pages":"Page 245"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}